Chairman & CEO, IBEX Technologies
Over 40 years pharmaceutical and related experience in healthcare and consumer product marketing. Currently, he is Chairman & CEO, IBEX Technologies, a manufacturer and marketer of proteins for biomedical use and arthritis assays widely used in osteoarthritis research.
Mr. Baehr began his career with Proctor & Gamble in product management. His career in pharmaceuticals began with CIBA-GEIGY where he served as Vice President & General Manager of the Pharmaceuticals Division, Canada, followed by Senior Vice President Marketing, CIBA-GEIGY US Pharmaceuticals Division. Subsequently, he joined Eastman Kodak as Corporate Vice President to head Kodak’s pharmaceutical diversification program culminating in the acquisition of Sterling Drug Inc. in New York then becoming Executive Vice President, Sterling-Winthrop Pharmaceuticals.
He has served on the board of the National Pharmaceutical Council in Washington, DC and a number of U.S. and Canadian biopharmaceutical companies. He also serves on the board of several hospitals including St. Barnabas Hospital in Livingston, N. J. and the Fox Chase Cancer Center in Philadelphia.
Mr. Baehr received his BA in Economics from the University of British Columbia, BC, Canada.
John Terrana has over 20 years of experience in the pharmaceutical and biologic industries and currently serves as a regional sales and marketing manager at Glaxo SmithKline (Nasdaq: GSK) where he has worked for the past 19 years. Mr. Terrana has also invested in several other early stage private companies in the healthcare sector including investing in Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX) where he served as a member of the board of directors. Mr. Terrana received his Bachelor’s Degree in Engineering at Utica College of Syracuse University.
Mark Rathjen serves as Managing Partner of Union Partner Advisors, a financial services company, where he has worked since November 2015 (Smithtown, NY). From January 2015 to November 2015, Mr. Rathjen served as Managing Director, Healthcare Trader and Institutional Sales at BTG (NY, NY). Prior to that, from April 2005 to December 2014, Mr. Rathjen served as Senior Managing Director, Head of Equity Trading and Sales Trading at Leerink Partners (NY, NY). Prior to that, Mr. Rathjen served as Vice President, Equity Trader, at Goldman Sachs (NYSE: GS), where he managed risk, price block trades, facilated corporate buybacks and served on the Technology Committee to develop new software, systems and applications among other duties. Mr. Rathjen has invested in over two dozen pre-IPO biopharmaceutical, med-tech and technology companies and currently serves as the Treasurer for the Knox School. Mr. Rathjen received his Bachelor’s Degree in Business from St. Bonaventure University.
Katie Jadhon has experience investing in early stage companies in a variety of industries for over ten years, including participating in both debt and equity financing rounds for several pre-IPO technology and biopharmaceutical companies. Ms. Jadhon received her Master’s Degree in Science Education from Cortland University.